Identity & Access Management Solutions Provider BIO-key’s Q1 Revenues Improved to $1.9M versus $0.5M in Q1’20 and $1.1M in Q4; Investor Call Today at 10am ET
BIO-key International, Inc. (BKYI) reported significant first-quarter results for 2021, with revenues increasing to $1.8M from $522k in the same period last year, driven by a 1193% rise in hardware sales and over 100% growth in license revenue.
The company secured a $1.2M contract extension and began technology deployments in Africa, generating $680k in hardware revenue. Despite a net loss of $0.7M, there was a notable reduction from a $3.5M loss in Q1 2020. BIO-key's cash position improved to $13.5M, and the firm aims for full-year revenues between $8M and $12M, indicating strong growth potential.
- Q1'21 revenue rose to $1.8M from $522k in Q1'20, a significant increase.
- Hardware revenue surged 1193%, mainly from projects in Africa, with $680k recorded.
- Secured a $1.2M contract extension from a Fortune 500 client for biometric security services.
- No debt with current assets totaling $17.8M, including $13.5M in cash.
- Full-year revenue guidance set at $8M to $12M, representing growth of over 250% from FY 2020.
- Q1'21 net loss of $0.7M, despite improved performance compared to a $3.5M loss in Q1'20.
- Gross margin decreased to 59.4% from 76.2% due to higher hardware sales proportion.
WALL, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (Nasdaq: BKYI), an innovative provider of biometric and multi-factor identity and access management (IAM) solutions for strong, convenient user authentication and large-scale identity applications, today reported results for its first quarter ended March 31, 2021 (Q1’21). BIO-key will host a conference call today at 10:00 a.m. ET (details below) to review its results and outlook.
Q1 & Recent Highlights:
- BIO-key began initial technology deployments for its large-scale ID projects in Africa, recording hardware revenue of
$680 k in Q1. - BIO-key secured a
$1.2M , three-year contract extension from a Fortune 500 telecommunications customer for fingerprint biometric security support services. - BIO-key added new higher education customer contracts in the quarter, extending the penetration of its PortalGuard™ identity and access management solution, while also converting several customers to the new cloud hosted version, PortalGuard IDaaS (Identity-as-a-Service).
- U.S. Department of Justice Division Leverages PortalGuard for Secure Authentication.
- West Coast State Increased Deployment of BIO-key’s Biometric Authentication Solution to secure access to Centralized Voter Registration database.
- BIO-key secured a U.S. patent for enabling next-generation continuous biometric user authentication, increasing its IP portfolio to 18 patents.
BIO-key CEO Michael DePasquale commented, “Our first quarter performance reflects the progress BIO-key has achieved over the past year in expanding and strengthening our business. We saw improved demand across the business in the first quarter, adding 29 new members to our Channel Alliance Partner program, positioning BIO-key to pursue a much broader base of opportunities on a global basis. Importantly, after several quarters of delay, we commenced initial hardware shipments in support of our large-scale ID projects in Africa and expect to see growing momentum as we progress through the year.
“We also continue to focus on innovation and new product development to provide greater functionality and value to our enterprise customers. We recently launched our new mobile app, BIO-key MobileAuthTM with PalmPositiveTM, a touchless palm-scan authentication technology for IOS and Android systems. This easy-to-use app requires no specialized hardware, as it utilizes the device’s camera, offers fast registration and enrollment while supporting multifactor and Single Sign-on solutions to streamline logins, while also making them more secure. MobileAuth builds upon our substantial biometric experience to add touchless biometric capabilities to the 16 authentication factors already supported by BIO-key’s PortalGuard® platform.
“PalmPositive is substantially more accurate than common, user-controlled mobile biometric authentication methods. Given the well-known deficiencies in traditional authentication methods, such as passwords, we believe enterprises are increasingly recognizing that they have no choice but to raise the bar on their authentication methods. We plan to add other identity-bound biometric authentication methods, such as voice and facial recognition, to the MobileAuth application in 2021. This will extend our leadership and support for strong multi-factor authentication (MFA) that offers the highest levels of integrity, security, accuracy, and availability across devices.
“We continue to see building demand for our PortalGuard solution within the higher education and enterprise markets, particularly our cloud-hosted, IDaaS solution, launched in Q4. PortalGuard IDaaS is an ideal solution for enterprises and institutions that are increasingly moving their IT infrastructure to the ‘asset-light’ cloud model. The transition to the cloud has been accelerated by the pandemic and the rapid rise in work-from-anywhere and study-from-home demands, and we believe the need to support remote access is here to stay. Off-premises access creates unprecedented IT security challenges as more users access mission critical data and applications outside the enterprise firewall. BIO-key helps enterprises meet these challenges with attractively priced IAM solutions supporting a wide array of MFA options, including our core, patented biometric capabilities.
“BIO-key’s Channel Alliance Partner (CAP) Program continues to build momentum and is expected to be a key component of our long-term growth strategy as it helps us to substantially expand our reach into new customers on a global basis. We have grown to 60 Partners over the past year, and we are working to double the size of this program in coming months, having expanded the program to include managed service providers (MSPs) and managed security service providers (MSSPs) in addition to system integrators and value-added resellers. We are targeting partners in key verticals, including financial services, government, and higher education – where our solutions and value proposition are well established.
“During the first quarter, we delivered our first shipment of biometric fingerprint scanners in support of our initiatives in Nigeria, recording initial revenue of
Outlook
“We believe we have the right team in place, a broad suite of solutions, a strong balance sheet, and the resources we need to drive growth. We are on-track to achieve our full year revenue guidance of
Financial Results
Q1’21 revenue grew significantly to
Q1’21 gross profit increased
Q1’21 operating expenses increased
BIO-key reported a net loss available to stockholders of
Financial Strength
BIO-key ended the first quarter with no debt and current assets of
| Conference Call Details | |
| Date / Time: | Today, Friday, May 14th at 10 a.m. ET |
| Call Dial In #: | 1-877-418-5460 U.S. or 1-412-717-9594 International |
| Live Webcast / Replay: | Investor Webcast & Replay – Available for 3 months. |
| Audio Replay: | 1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 10156403 |
About BIO-key International, Inc. (www.bio-key.com)
BIO-key has over two decades of expertise in providing authentication technology for thousands of organizations and millions of users and is revolutionizing authentication with biometric-centric, multi-factor identity and access management (IAM) solutions. Its PortalGuard IAM solution provides convenient and secure access to devices, information, applications, and high-value transactions. BIO-key's patented software and hardware solutions, with industry-leading biometric capabilities, enable large-scale on-premise and Identity-as-a-Service (IDaaS) solutions as well as customized enterprise and cloud solutions.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to execute and deliver on contracts in Africa; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of PistolStar into our business; the duration and severity of the current coronavirus COVID-19 pandemic and its effect on our business operations, sales cycles, personnel, and the geographic markets in which we operate; delays in the development of products and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2020 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, the Company undertakes no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
Engage with BIO-key
Facebook – Corporate: https://www.facebook.com/BIOkeyInternational/
LinkedIn – Corporate: https://www.linkedin.com/company/bio-key-international
Twitter – Corporate: @BIOkeyIntl
Twitter – Investors: @BIO_keyIR
StockTwits: BIO_keyIR
| Media Contact | Investor Contact |
| Erin Knapp | William Jones, David Collins |
| Matter Communications | Catalyst IR |
| BIO-key@matternow.com | BKYI@catalyst-ir.com |
| 914-260-3158 | 212-924-9800 |
BIO-KEY International, Inc. and Subsidiaries
PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31, 2021 | December 31, 2020 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Cash and cash equivalents | $ | 13,528,521 | $ | 16,993,096 | ||||
| Accounts receivable, net | 1,432,248 | 548,049 | ||||||
| Due from factor | 49,808 | 60,453 | ||||||
| Note receivable | - | 295,000 | ||||||
| Inventory | 600,447 | 330,947 | ||||||
| Prepaid expenses and other | 1,706,161 | 201,507 | ||||||
| Investment – debt security | 512,821 | 512,821 | ||||||
| Total current assets | 17,830,006 | 1,894,873 | ||||||
| Resalable software license rights | 56,361 | 58,882 | ||||||
| Equipment and leasehold improvements, net | 69,985 | 81,793 | ||||||
| Capitalized contract costs, net | 170,219 | 165,315 | ||||||
| Deposits and other assets | 8,712 | 8,712 | ||||||
| Note receivable | 295,000 | - | ||||||
| Operating lease right-of-use assets | 430,206 | 487,325 | ||||||
| Intangible assets, net | 1,460,130 | 1,514,146 | ||||||
| Goodwill | 1,262,526 | 1,262,526 | ||||||
| Total non-current assets | 3,753,139 | 3,578,699 | ||||||
| TOTAL ASSETS | $ | 21,583,145 | $ | 22,520,572 | ||||
| LIABILITIES | ||||||||
| Accounts payable | $ | 309,323 | $ | 244,158 | ||||
| Accrued liabilities | 515,952 | 508,487 | ||||||
| Note payable – PistolStar acquisition, net of debt discount | - | 232,000 | ||||||
| Deferred revenue – current | 524,836 | 657,349 | ||||||
| Operating lease liabilities, current portion | 230,072 | 234,309 | ||||||
| Total current liabilities | 1,580,183 | 1,876,303 | ||||||
| Deferred revenue – long term | 49,393 | 44,987 | ||||||
| Operating lease liabilities, net of current portion | 211,442 | 264,163 | ||||||
| Total non-current liabilities | 260,835 | 309,150 | ||||||
| TOTAL LIABILITIES | 1,841,018 | 2,185,453 | ||||||
| Commitments and Contingencies | ||||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Common stock — authorized, 170,000,000 shares; issued and outstanding; 7,817,913 and 7,814,572 of $.0001 par value at March 31, 2021 and December 31, 2020, respectively | 782 | 782 | ||||||
| Additional paid-in capital | 119,982,465 | 119,844,026 | ||||||
| Accumulated deficit | (100,241,120 | ) | (99,509,689 | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY | 19,742,127 | 20,335,119 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 21,583,145 | $ | 22,520,572 | ||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-8 reverse stock split, which was effective November 20, 2020.
BIO-KEY International, Inc. and Subsidiaries
PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| Three months ended March 31, | ||||||||
| 2021 | 2020 | |||||||
| Revenues | ||||||||
| Services | $ | 380,022 | $ | 207,523 | ||||
| License fees | 478,958 | 235,345 | ||||||
| Hardware | 1,029,658 | 79,617 | ||||||
| Total revenues | 1,888,638 | 522,485 | ||||||
| Costs and other expenses | ||||||||
| Cost of services | 175,944 | 70,445 | ||||||
| Cost of license fees | 38,969 | 10,456 | ||||||
| Cost of hardware | 551,722 | 43,362 | ||||||
| Total cost of goods sold | 766,635 | 124,263 | ||||||
| Gross Profit | 1,122,003 | 398,222 | ||||||
| Operating Expenses | ||||||||
| Selling, general and administrative | 1,396,398 | 1,381,399 | ||||||
| Research, development and engineering | 441,651 | 336,889 | ||||||
| Total Operating Expenses | 1,838,049 | 1,718,288 | ||||||
| Operating loss | (716,046 | ) | (1,320,066 | ) | ||||
| Other income (expenses) | ||||||||
| Interest income | 2,615 | 1 | ||||||
| Interest expense | (18,000 | ) | (1,551,141 | ) | ||||
| Loss on extinguishment of debt | - | (499,076 | ) | |||||
| Total Other Income (Expenses) | (15,385 | ) | (2,050,216 | ) | ||||
| Net loss | (731,431 | ) | (3,370,282 | ) | ||||
| Deemed dividends related to down-round features | - | (112,686 | ) | |||||
| Net loss available to common stockholders | $ | (731,431 | ) | $ | (3,482,968 | ) | ||
| Basic Loss per Common Share | $ | (0.09 | ) | $ | (1.84 | ) | ||
| Weighted Average Shares Outstanding: | ||||||||
| Basic | 7,773,688 | 1,895,690 | ||||||
BIO-key’s weighted average shares outstanding in the 2021 and 2020 periods have been adjusted to reflect BIO-key’s 1-for-8 reverse stock split, which was effective November 20, 2020.
FAQ
What were BIO-key's Q1 2021 revenue figures?
What is the impact of the contract extension secured by BIO-key in Q1 2021?
What was the net loss reported by BIO-key in Q1 2021?
How much cash does BIO-key have as of Q1 2021?
What is BIO-key's revenue guidance for FY 2021?
